25 XP   0   0   10

Aurobindo Pharma Limited
Buy, Hold or Sell?

Let's analyse Aurobindo together

PenkeI guess you are interested in Aurobindo Pharma Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aurobindo Pharma Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Aurobindo Pharma Limited

I send you an email if I find something interesting about Aurobindo Pharma Limited.

Quick analysis of Aurobindo (30 sec.)










What can you expect buying and holding a share of Aurobindo? (30 sec.)

How much money do you get?

How much money do you get?
INR0.36
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR458.27
Expected worth in 1 year
INR613.77
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR185.50
Return On Investment
16.4%

For what price can you sell your share?

Current Price per Share
INR1,131.30
Expected price per share
INR984.30 - INR1,154
How sure are you?
50%

1. Valuation of Aurobindo (5 min.)




Live pricePrice per Share (EOD)

INR1,131.30

Intrinsic Value Per Share

INR-573.37 - INR160.69

Total Value Per Share

INR-115.10 - INR618.96

2. Growth of Aurobindo (5 min.)




Is Aurobindo growing?

Current yearPrevious yearGrowGrow %
How rich?$3.2b$2.9b$273.3m8.5%

How much money is Aurobindo making?

Current yearPrevious yearGrowGrow %
Making money$231.3m$317.7m-$86.4m-37.4%
Net Profit Margin7.8%11.3%--

How much money comes from the company's main activities?

3. Financial Health of Aurobindo (5 min.)




What can you expect buying and holding a share of Aurobindo? (5 min.)

Welcome investor! Aurobindo's management wants to use your money to grow the business. In return you get a share of Aurobindo.

What can you expect buying and holding a share of Aurobindo?

First you should know what it really means to hold a share of Aurobindo. And how you can make/lose money.

Speculation

The Price per Share of Aurobindo is INR1,131. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aurobindo.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aurobindo, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR458.27. Based on the TTM, the Book Value Change Per Share is INR38.87 per quarter. Based on the YOY, the Book Value Change Per Share is INR45.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR7.50 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aurobindo.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.390.0%0.390.0%0.540.0%0.620.1%0.500.0%
Usd Book Value Change Per Share0.470.0%0.470.0%0.540.0%0.620.1%0.500.0%
Usd Dividend Per Share0.090.0%0.090.0%0.050.0%0.050.0%0.040.0%
Usd Total Gains Per Share0.560.0%0.560.0%0.600.1%0.670.1%0.540.0%
Usd Price Per Share6.20-6.20-8.03-7.83-8.37-
Price to Earnings Ratio15.69-15.69-14.80-13.63-19.13-
Price-to-Total Gains Ratio11.13-11.13-13.48-12.32-19.09-
Price to Book Ratio1.13-1.13-1.60-1.97-4.52-
Price-to-Total Gains Ratio11.13-11.13-13.48-12.32-19.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share13.5756
Number of shares73
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.090.05
Usd Book Value Change Per Share0.470.62
Usd Total Gains Per Share0.560.67
Gains per Quarter (73 shares)40.6349.12
Gains per Year (73 shares)162.50196.49
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12613615315181186
25327231630363382
37940947945544578
410554564260726774
513168180575907970
61588179689010891166
7184954113110512701362
82101090129412014511558
92371226145713616331754
102631362162015118141950

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.01.00.095.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%18.02.00.090.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.01.00.095.0%

Fundamentals of Aurobindo

About Aurobindo Pharma Limited

Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries. In addition, it offers AuroSource, a contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for penicillin's, cephalosporins, and non beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Fundamental data was last updated by Penke on 2024-04-13 21:08:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Aurobindo Pharma Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Aurobindo earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 7.8% means that ₹0.08 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aurobindo Pharma Limited:

  • The MRQ is 7.8%. The company is making a profit. +1
  • The TTM is 7.8%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ7.8%TTM7.8%0.0%
TTM7.8%YOY11.3%-3.5%
TTM7.8%5Y13.6%-5.8%
5Y13.6%10Y14.1%-0.5%
1.1.2. Return on Assets

Shows how efficient Aurobindo is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.8% Return on Assets means that Aurobindo generated ₹0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aurobindo Pharma Limited:

  • The MRQ is 4.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.8%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.8%TTM4.8%0.0%
TTM4.8%YOY7.8%-3.0%
TTM4.8%5Y9.8%-5.0%
5Y9.8%10Y11.2%-1.4%
1.1.3. Return on Equity

Shows how efficient Aurobindo is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • 7.2% Return on Equity means Aurobindo generated ₹0.07 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aurobindo Pharma Limited:

  • The MRQ is 7.2%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 7.2%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ7.2%TTM7.2%0.0%
TTM7.2%YOY10.8%-3.6%
TTM7.2%5Y15.9%-8.7%
5Y15.9%10Y21.8%-5.9%

1.2. Operating Efficiency of Aurobindo Pharma Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Aurobindo is operating .

  • Measures how much profit Aurobindo makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 11.2% means the company generated ₹0.11  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aurobindo Pharma Limited:

  • The MRQ is 11.2%. The company is operating less efficient.
  • The TTM is 11.2%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ11.2%TTM11.2%0.0%
TTM11.2%YOY15.0%-3.8%
TTM11.2%5Y15.7%-4.5%
5Y15.7%10Y18.0%-2.3%
1.2.2. Operating Ratio

Measures how efficient Aurobindo is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.90 means that the operating costs are ₹0.90 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Aurobindo Pharma Limited:

  • The MRQ is 0.898. The company is less efficient in keeping operating costs low.
  • The TTM is 0.898. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.898TTM0.8980.000
TTM0.898YOY0.859+0.039
TTM0.8985Y0.846+0.052
5Y0.84610Y0.818+0.027

1.3. Liquidity of Aurobindo Pharma Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Aurobindo is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.87 means the company has ₹1.87 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Aurobindo Pharma Limited:

  • The MRQ is 1.875. The company is able to pay all its short-term debts. +1
  • The TTM is 1.875. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.875TTM1.8750.000
TTM1.875YOY2.222-0.347
TTM1.8755Y1.734+0.140
5Y1.73410Y1.549+0.185
1.3.2. Quick Ratio

Measures if Aurobindo is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.16 means the company can pay off ₹1.16 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aurobindo Pharma Limited:

  • The MRQ is 1.157. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.157. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.157TTM1.1570.000
TTM1.157YOY1.154+0.003
TTM1.1575Y0.903+0.254
5Y0.90310Y0.797+0.105

1.4. Solvency of Aurobindo Pharma Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Aurobindo assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aurobindo to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.33 means that Aurobindo assets are financed with 32.7% credit (debt) and the remaining percentage (100% - 32.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aurobindo Pharma Limited:

  • The MRQ is 0.327. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.327. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.327TTM0.3270.000
TTM0.327YOY0.276+0.051
TTM0.3275Y0.370-0.043
5Y0.37010Y0.453-0.083
1.4.2. Debt to Equity Ratio

Measures if Aurobindo is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 48.6% means that company has ₹0.49 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aurobindo Pharma Limited:

  • The MRQ is 0.486. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.486. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.486TTM0.4860.000
TTM0.486YOY0.380+0.105
TTM0.4865Y0.607-0.121
5Y0.60710Y0.902-0.295

2. Market Valuation of Aurobindo Pharma Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Aurobindo generates.

  • Above 15 is considered overpriced but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 15.69 means the investor is paying ₹15.69 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aurobindo Pharma Limited:

  • The EOD is 34.390. Based on the earnings, the company is overpriced. -1
  • The MRQ is 15.693. Based on the earnings, the company is fair priced.
  • The TTM is 15.693. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD34.390MRQ15.693+18.697
MRQ15.693TTM15.6930.000
TTM15.693YOY14.803+0.891
TTM15.6935Y13.629+2.065
5Y13.62910Y19.134-5.505
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aurobindo Pharma Limited:

  • The EOD is -198.673. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -90.661. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -90.661. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-198.673MRQ-90.661-108.012
MRQ-90.661TTM-90.6610.000
TTM-90.661YOY16.956-107.617
TTM-90.6615Y548.528-639.190
5Y548.52810Y334.278+214.250
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Aurobindo is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.13 means the investor is paying ₹1.13 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Aurobindo Pharma Limited:

  • The EOD is 2.469. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.127. Based on the equity, the company is underpriced. +1
  • The TTM is 1.127. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.469MRQ1.127+1.342
MRQ1.127TTM1.1270.000
TTM1.127YOY1.595-0.469
TTM1.1275Y1.965-0.839
5Y1.96510Y4.521-2.556
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Aurobindo Pharma Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--38.87438.8740%45.142-14%51.779-25%41.361-6%
Book Value Per Share--458.270458.2700%419.396+9%355.183+29%239.286+92%
Current Ratio--1.8751.8750%2.222-16%1.734+8%1.549+21%
Debt To Asset Ratio--0.3270.3270%0.276+19%0.370-12%0.453-28%
Debt To Equity Ratio--0.4860.4860%0.380+28%0.607-20%0.902-46%
Dividend Per Share--7.5017.5010%4.500+67%4.298+75%3.309+127%
Eps--32.89632.8960%45.195-27%51.611-36%42.016-22%
Free Cash Flow Per Share---5.694-5.6940%39.455-114%21.846-126%15.915-136%
Free Cash Flow To Equity Per Share--25.27225.2720%-11.220+144%13.149+92%10.099+150%
Gross Profit Margin--0.1250.1250%0.408-69%0.449-72%0.489-74%
Intrinsic Value_10Y_max--160.692--------
Intrinsic Value_10Y_min---573.373--------
Intrinsic Value_1Y_max--20.654--------
Intrinsic Value_1Y_min---2.610--------
Intrinsic Value_3Y_max--58.588--------
Intrinsic Value_3Y_min---55.391--------
Intrinsic Value_5Y_max--92.340--------
Intrinsic Value_5Y_min---159.881--------
Market Cap662872799750.400+54%302491012880.000302491012880.0000%391993196352.000-23%382354499670.400-21%408675465848.768-26%
Net Profit Margin--0.0780.0780%0.113-31%0.136-43%0.141-44%
Operating Margin--0.1120.1120%0.150-25%0.157-29%0.180-38%
Operating Ratio--0.8980.8980%0.859+5%0.846+6%0.818+10%
Pb Ratio2.469+54%1.1271.1270%1.595-29%1.965-43%4.521-75%
Pe Ratio34.390+54%15.69315.6930%14.803+6%13.629+15%19.134-18%
Price Per Share1131.300+54%516.250516.2500%669.000-23%652.550-21%697.471-26%
Price To Free Cash Flow Ratio-198.673-119%-90.661-90.6610%16.956-635%548.528-117%334.278-127%
Price To Total Gains Ratio24.394+54%11.13211.1320%13.476-17%12.322-10%19.094-42%
Quick Ratio--1.1571.1570%1.154+0%0.903+28%0.797+45%
Return On Assets--0.0480.0480%0.078-38%0.098-51%0.112-57%
Return On Equity--0.0720.0720%0.108-33%0.159-55%0.218-67%
Total Gains Per Share--46.37646.3760%49.643-7%56.077-17%44.670+4%
Usd Book Value--3222222000.0003222222000.0000%2948886000.000+9%2497386720.000+29%1682483760.000+92%
Usd Book Value Change Per Share--0.4660.4660%0.542-14%0.621-25%0.496-6%
Usd Book Value Per Share--5.4995.4990%5.033+9%4.262+29%2.871+92%
Usd Dividend Per Share--0.0900.0900%0.054+67%0.052+75%0.040+127%
Usd Eps--0.3950.3950%0.542-27%0.619-36%0.504-22%
Usd Free Cash Flow---40038000.000-40038000.0000%277420800.000-114%153602640.000-126%111902160.000-136%
Usd Free Cash Flow Per Share---0.068-0.0680%0.473-114%0.262-126%0.191-136%
Usd Free Cash Flow To Equity Per Share--0.3030.3030%-0.135+144%0.158+92%0.121+150%
Usd Market Cap7954473597.005+54%3629892154.5603629892154.5600%4703918356.224-23%4588253996.045-21%4904105590.185-26%
Usd Price Per Share13.576+54%6.1956.1950%8.028-23%7.831-21%8.370-26%
Usd Profit--231300000.000231300000.0000%317778000.000-27%374078400.000-38%300504600.000-23%
Usd Revenue--2954055600.0002954055600.0000%2803986000.000+5%2748132240.000+7%2149195200.000+37%
Usd Total Gains Per Share--0.5570.5570%0.596-7%0.673-17%0.536+4%
 EOD+5 -3MRQTTM+0 -0YOY+12 -245Y+15 -2110Y+18 -18

3.2. Fundamental Score

Let's check the fundamental score of Aurobindo Pharma Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1534.390
Price to Book Ratio (EOD)Between0-12.469
Net Profit Margin (MRQ)Greater than00.078
Operating Margin (MRQ)Greater than00.112
Quick Ratio (MRQ)Greater than11.157
Current Ratio (MRQ)Greater than11.875
Debt to Asset Ratio (MRQ)Less than10.327
Debt to Equity Ratio (MRQ)Less than10.486
Return on Equity (MRQ)Greater than0.150.072
Return on Assets (MRQ)Greater than0.050.048
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Aurobindo Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.854
Ma 20Greater thanMa 501,104.885
Ma 50Greater thanMa 1001,063.669
Ma 100Greater thanMa 2001,070.149
OpenGreater thanClose1,109.000
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-03-312020-03-312021-03-312022-03-312023-03-31
Long-term Liabilities Other  113,000761,800874,800-479,800395,000-97,300297,700-15,450,900-15,153,200



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets398,899,900
Total Liabilities130,381,400
Total Stockholder Equity268,398,500
 As reported
Total Liabilities 130,381,400
Total Stockholder Equity+ 268,398,500
Total Assets = 398,899,900

Assets

Total Assets398,899,900
Total Current Assets215,456,700
Long-term Assets183,443,200
Total Current Assets
Cash And Cash Equivalents 43,962,900
Short-term Investments 21,292,600
Net Receivables 46,401,900
Inventory 85,112,300
Other Current Assets 18,687,000
Total Current Assets  (as reported)215,456,700
Total Current Assets  (calculated)215,456,700
+/-0
Long-term Assets
Property Plant Equipment 124,917,800
Goodwill 5,960,700
Intangible Assets 33,258,500
Long-term Assets Other 8,614,000
Long-term Assets  (as reported)183,443,200
Long-term Assets  (calculated)172,751,000
+/- 10,692,200

Liabilities & Shareholders' Equity

Total Current Liabilities114,937,800
Long-term Liabilities15,443,600
Total Stockholder Equity268,398,500
Total Current Liabilities
Short-term Debt 43,457,200
Short Long Term Debt 42,425,600
Accounts payable 38,713,100
Other Current Liabilities 11,432,500
Total Current Liabilities  (as reported)114,937,800
Total Current Liabilities  (calculated)136,028,400
+/- 21,090,600
Long-term Liabilities
Long term Debt Total 9,404,900
Other Liabilities 6,038,700
Long-term Liabilities  (as reported)15,443,600
Long-term Liabilities  (calculated)15,443,600
+/-0
Total Stockholder Equity
Common Stock585,900
Retained Earnings 240,130,300
Accumulated Other Comprehensive Income 23,503,400
Capital Surplus 4,178,900
Total Stockholder Equity (as reported)268,398,500
Total Stockholder Equity (calculated)268,398,500
+/-0
Other
Capital Stock585,900
Cash And Equivalents27,296,600
Cash and Short Term Investments 65,255,500
Common Stock Shares Outstanding 585,939
Current Deferred Revenue21,335,000
Liabilities and Stockholders Equity 398,899,900
Net Debt 8,899,200
Net Invested Capital 317,013,700
Net Tangible Assets 229,179,300
Net Working Capital 100,518,900
Property Plant and Equipment Gross 124,917,800
Short Long Term Debt Total 52,862,100



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-312006-03-312005-03-312004-03-31
> Total Assets 
18,659,000
21,297,800
26,894,600
35,065,000
36,344,800
42,264,700
47,913,100
58,772,400
62,376,300
72,778,400
94,898,200
129,144,800
156,993,500
162,494,200
211,052,000
264,543,700
289,263,500
338,539,900
339,217,200
398,899,900
398,899,900339,217,200338,539,900289,263,500264,543,700211,052,000162,494,200156,993,500129,144,80094,898,20072,778,40062,376,30058,772,40047,913,10042,264,70036,344,80035,065,00026,894,60021,297,80018,659,000
   > Total Current Assets 
9,590,200
10,187,100
14,556,800
21,349,100
20,590,800
22,889,700
25,059,300
33,921,400
32,640,400
41,367,500
56,311,800
82,988,000
100,014,700
92,061,800
121,878,400
153,645,100
164,125,000
198,235,100
181,226,900
215,456,700
215,456,700181,226,900198,235,100164,125,000153,645,100121,878,40092,061,800100,014,70082,988,00056,311,80041,367,50032,640,40033,921,40025,059,30022,889,70020,590,80021,349,10014,556,80010,187,1009,590,200
       Cash And Cash Equivalents 
622,600
593,900
2,019,300
5,824,600
2,825,700
1,276,500
728,300
1,881,900
708,600
2,084,500
1,785,800
4,691,100
8,343,900
4,894,400
12,159,000
18,554,300
27,637,100
53,734,700
41,625,100
43,962,900
43,962,90041,625,10053,734,70027,637,10018,554,30012,159,0004,894,4008,343,9004,691,1001,785,8002,084,500708,6001,881,900728,3001,276,5002,825,7005,824,6002,019,300593,900622,600
       Short-term Investments 
300
300
500
500
600
0
0
0
186,800
400
300
196,500
200
240,600
457,400
735,000
784,600
2,477,300
3,951,300
21,292,600
21,292,6003,951,3002,477,300784,600735,000457,400240,600200196,500300400186,800000600500500300300
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
28,555,100
38,108,900
46,066,800
38,454,300
43,121,800
59,644,100
43,846,700
37,269,300
44,561,900
46,401,900
46,401,90044,561,90037,269,30043,846,70059,644,10043,121,80038,454,30046,066,80038,108,90028,555,1000000000000
       Inventory 
3,193,800
3,754,600
4,718,100
6,544,000
7,950,300
8,776,300
11,024,500
14,552,600
15,455,600
19,235,900
23,675,400
36,113,000
40,881,000
43,305,400
58,584,100
72,456,000
76,998,700
90,265,700
75,538,500
85,112,300
85,112,30075,538,50090,265,70076,998,70072,456,00058,584,10043,305,40040,881,00036,113,00023,675,40019,235,90015,455,60014,552,60011,024,5008,776,3007,950,3006,544,0004,718,1003,754,6003,193,800
       Other Current Assets 
5,773,500
5,838,300
7,818,900
8,980,000
9,814,200
12,836,900
13,306,500
17,486,900
16,289,400
20,046,700
30,850,300
41,987,400
50,789,600
43,621,400
50,677,900
2,255,700
14,857,900
14,488,100
15,550,100
18,687,000
18,687,00015,550,10014,488,10014,857,9002,255,70050,677,90043,621,40050,789,60041,987,40030,850,30020,046,70016,289,40017,486,90013,306,50012,836,9009,814,2008,980,0007,818,9005,838,3005,773,500
   > Long-term Assets 
9,068,800
11,110,700
12,337,800
13,715,900
15,754,000
19,375,000
22,853,800
24,851,000
29,735,900
31,410,900
38,586,400
46,156,800
56,978,800
70,432,400
89,173,600
110,898,600
125,138,500
140,304,800
157,990,300
183,443,200
183,443,200157,990,300140,304,800125,138,500110,898,60089,173,60070,432,40056,978,80046,156,80038,586,40031,410,90029,735,90024,851,00022,853,80019,375,00015,754,00013,715,90012,337,80011,110,7009,068,800
       Property Plant Equipment 
8,670,400
10,571,600
11,491,900
12,750,200
14,164,200
18,370,500
21,687,200
17,386,000
25,871,700
26,386,400
28,068,000
32,721,500
43,925,500
53,204,100
61,361,000
70,355,900
81,166,300
93,155,100
106,659,900
124,917,800
124,917,800106,659,90093,155,10081,166,30070,355,90061,361,00053,204,10043,925,50032,721,50028,068,00026,386,40025,871,70017,386,00021,687,20018,370,50014,164,20012,750,20011,491,90010,571,6008,670,400
       Goodwill 
0
0
235,000
538,600
531,600
525,500
480,700
0
541,400
554,400
763,800
5,333,000
4,490,400
4,063,000
8,165,500
8,325,100
9,159,400
4,289,000
4,754,200
5,960,700
5,960,7004,754,2004,289,0009,159,4008,325,1008,165,5004,063,0004,490,4005,333,000763,800554,400541,4000480,700525,500531,600538,600235,00000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
197,530
1,330
1,229,327
2,458,400
3,115,100
3,601,900
0
0
0
0
00003,601,9003,115,1002,458,4001,229,3271,330197,5300000000000
       Intangible Assets 
341,500
536,500
608,000
424,400
452,700
454,700
640,600
0
1,987,500
1,633,000
1,482,100
3,198,200
4,219,500
5,651,500
11,510,700
22,752,100
23,498,400
26,907,000
31,378,700
33,258,500
33,258,50031,378,70026,907,00023,498,40022,752,10011,510,7005,651,5004,219,5003,198,2001,482,1001,633,0001,987,5000640,600454,700452,700424,400608,000536,500341,500
       Long-term Assets Other 
300
300
500
-193,100
600
2,600
3,600
7,421,500
1,269,200
2,615,100
8,074,700
5,051,700
4,341,300
3,557,500
3,870,700
4,746,600
4,135,600
7,114,800
6,128,700
8,614,000
8,614,0006,128,7007,114,8004,135,6004,746,6003,870,7003,557,5004,341,3005,051,7008,074,7002,615,1001,269,2007,421,5003,6002,600600-193,100500300300
> Total Liabilities 
11,409,100
14,153,000
18,721,600
26,193,700
25,072,600
29,820,600
29,579,000
34,232,900
38,877,700
46,610,800
57,140,000
77,327,500
85,830,700
78,562,900
94,229,600
125,620,000
121,158,300
119,250,000
93,476,700
130,381,400
130,381,40093,476,700119,250,000121,158,300125,620,00094,229,60078,562,90085,830,70077,327,50057,140,00046,610,80038,877,70034,232,90029,579,00029,820,60025,072,60026,193,70018,721,60014,153,00011,409,100
   > Total Current Liabilities 
2,657,300
3,200,000
4,265,300
4,706,200
5,869,000
5,700,500
7,079,900
8,862,800
29,150,500
34,358,200
42,200,400
61,364,000
74,758,800
66,223,200
86,806,200
120,429,000
113,867,500
106,651,500
81,559,800
114,937,800
114,937,80081,559,800106,651,500113,867,500120,429,00086,806,20066,223,20074,758,80061,364,00042,200,40034,358,20029,150,5008,862,8007,079,9005,700,5005,869,0004,706,2004,265,3003,200,0002,657,300
       Short-term Debt 
400
100
57,600
66,300
103,600
116,000
136,800
0
21,313,100
22,872,000
24,897,800
30,896,000
38,547,700
31,827,400
43,187,400
67,868,100
60,368,100
51,152,100
27,111,400
43,457,200
43,457,20027,111,40051,152,10060,368,10067,868,10043,187,40031,827,40038,547,70030,896,00024,897,80022,872,00021,313,1000136,800116,000103,60066,30057,600100400
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
37,691,400
5,875,200
6,255,800
31,827,400
43,187,400
67,710,900
54,223,000
50,145,900
21,235,600
42,425,600
42,425,60021,235,60050,145,90054,223,00067,710,90043,187,40031,827,4006,255,8005,875,20037,691,4000000000000
       Accounts payable 
2,251,700
2,902,800
3,861,300
4,205,100
4,631,700
5,147,700
6,044,000
0
6,601,400
9,687,400
13,512,000
20,511,200
25,267,700
24,882,700
26,274,400
26,771,300
25,450,100
27,946,800
27,030,500
38,713,100
38,713,10027,030,50027,946,80025,450,10026,771,30026,274,40024,882,70025,267,70020,511,20013,512,0009,687,4006,601,40006,044,0005,147,7004,631,7004,205,1003,861,3002,902,8002,251,700
       Other Current Liabilities 
405,200
297,100
346,400
434,800
1,133,700
436,800
899,100
8,862,800
1,236,000
1,798,800
3,790,600
9,956,800
10,943,400
9,248,500
16,913,300
25,126,900
1,149,300
1,116,200
1,279,400
11,432,500
11,432,5001,279,4001,116,2001,149,30025,126,90016,913,3009,248,50010,943,4009,956,8003,790,6001,798,8001,236,0008,862,800899,100436,8001,133,700434,800346,400297,100405,200
   > Long-term Liabilities 
8,751,800
10,953,000
14,456,300
21,487,500
19,203,600
24,120,100
22,499,100
25,370,100
9,727,200
12,252,600
14,939,600
15,963,500
11,071,900
12,339,700
7,423,400
5,191,000
7,290,800
12,598,500
11,916,900
15,443,600
15,443,60011,916,90012,598,5007,290,8005,191,0007,423,40012,339,70011,071,90015,963,50014,939,60012,252,6009,727,20025,370,10022,499,10024,120,10019,203,60021,487,50014,456,30010,953,0008,751,800
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
7,428,100
1,814,000
4,512,000
1,799,500
2,644,100
4,886,900
5,678,200
9,404,900
9,404,9005,678,2004,886,9002,644,1001,799,5004,512,0001,814,0007,428,100000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
2,146,000
2,348,800
473,200
884,300
3,017,100
3,614,700
4,538,800
8,252,600
6,238,700
6,038,700
6,038,7006,238,7008,252,6004,538,8003,614,7003,017,100884,300473,2002,348,8002,146,0000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
157,600
13,300
95,500
74,100
19,000
37,600
78,200
1,361,000
1,791,600
0
01,791,6001,361,00078,20037,60019,00074,10095,50013,300157,6000000000000
> Total Stockholder Equity
7,241,800
7,132,400
8,148,700
8,860,100
11,240,200
12,412,600
18,290,800
24,448,300
23,396,500
26,057,600
37,501,500
51,559,100
70,567,300
83,910,500
116,804,200
138,907,800
168,103,800
219,298,700
245,759,800
268,398,500
268,398,500245,759,800219,298,700168,103,800138,907,800116,804,20083,910,50070,567,30051,559,10037,501,50026,057,60023,396,50024,448,30018,290,80012,412,60011,240,2008,860,1008,148,7007,132,4007,241,800
   Common Stock
253,900
253,900
266,300
266,700
268,800
268,800
278,600
291,100
291,100
291,200
291,500
292,000
585,200
585,900
585,900
585,900
585,900
585,900
585,900
585,900
585,900585,900585,900585,900585,900585,900585,900585,200292,000291,500291,200291,100291,100278,600268,800268,800266,700266,300253,900253,900
   Retained Earnings Total Equity00000000000000000000
   Accumulated Other Comprehensive Income 
-1,393,900
-1,971,500
-2,639,300
-3,075,000
-4,073,700
-5,543,100
-6,644,200
-6,404,800
-7,975,900
-9,897,300
-12,297,400
-15,369,200
-18,707,000
-7,167,600
-11,842,700
-17,346,800
13,057,900
13,166,300
15,804,900
23,503,400
23,503,40015,804,90013,166,30013,057,900-17,346,800-11,842,700-7,167,600-18,707,000-15,369,200-12,297,400-9,897,300-7,975,900-6,404,800-6,644,200-5,543,100-4,073,700-3,075,000-2,639,300-1,971,500-1,393,900
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
4,096,800
4,173,100
4,175,700
4,176,400
4,178,900
4,178,900
4,178,900
4,178,900
4,178,9004,178,9004,178,9004,178,9004,176,4004,175,7004,173,1004,096,800000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
8,381,800
8,850,000
9,738,100
9,263,000
10,751,200
12,802,000
24,656,400
30,562,000
18,628,500
21,277,100
25,587,000
28,717,800
32,709,500
18,654,000
25,943,400
31,507,200
3,874,500
4,178,900
4,178,900
4,178,900
4,178,9004,178,9004,178,9003,874,50031,507,20025,943,40018,654,00032,709,50028,717,80025,587,00021,277,10018,628,50030,562,00024,656,40012,802,00010,751,2009,263,0009,738,1008,850,0008,381,800



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue246,171,300
Cost of Revenue-112,932,600
Gross Profit133,238,700133,238,700
 
Operating Income (+$)
Gross Profit133,238,700
Operating Expense-108,102,300
Operating Income25,514,70025,136,400
 
Operating Expense (+$)
Research Development395,100
Selling General Administrative6,624,100
Selling And Marketing Expenses16,857,600
Operating Expense108,102,30023,876,800
 
Net Interest Income (+$)
Interest Income988,600
Interest Expense-1,404,800
Other Finance Cost-988,600
Net Interest Income-1,404,800
 
Pretax Income (+$)
Operating Income25,514,700
Net Interest Income-1,404,800
Other Non-Operating Income Expenses0
Income Before Tax (EBT)26,125,00024,904,400
EBIT - interestExpense = 26,125,000
26,123,500
20,679,800
Interest Expense1,404,800
Earnings Before Interest and Taxes (EBIT)27,529,80027,529,800
Earnings Before Interest and Taxes (EBITDA)39,975,600
 
After tax Income (+$)
Income Before Tax26,125,000
Tax Provision-6,848,500
Net Income From Continuing Ops19,276,50019,276,500
Net Income19,275,000
Net Income Applicable To Common Shares19,275,000
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses221,034,900
Total Other Income/Expenses Net610,3001,404,800
 

Technical Analysis of Aurobindo
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aurobindo. The general trend of Aurobindo is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aurobindo's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aurobindo Pharma Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1,151 < 1,154.

The bearish price targets are: 1,069 > 996.50 > 984.30.

Tweet this
Aurobindo Pharma Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aurobindo Pharma Limited. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aurobindo Pharma Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aurobindo Pharma Limited. The current macd is 11.12.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aurobindo price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Aurobindo. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Aurobindo price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Aurobindo Pharma Limited Daily Moving Average Convergence/Divergence (MACD) ChartAurobindo Pharma Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aurobindo Pharma Limited. The current adx is 15.67.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Aurobindo shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Aurobindo Pharma Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aurobindo Pharma Limited. The current sar is 1,079.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Aurobindo Pharma Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aurobindo Pharma Limited. The current rsi is 59.85. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Aurobindo Pharma Limited Daily Relative Strength Index (RSI) ChartAurobindo Pharma Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aurobindo Pharma Limited. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aurobindo price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Aurobindo Pharma Limited Daily Stochastic Oscillator ChartAurobindo Pharma Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aurobindo Pharma Limited. The current cci is 82.05.

Aurobindo Pharma Limited Daily Commodity Channel Index (CCI) ChartAurobindo Pharma Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aurobindo Pharma Limited. The current cmo is 25.60.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Aurobindo Pharma Limited Daily Chande Momentum Oscillator (CMO) ChartAurobindo Pharma Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aurobindo Pharma Limited. The current willr is -14.71801926.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Aurobindo Pharma Limited Daily Williams %R ChartAurobindo Pharma Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aurobindo Pharma Limited.

Aurobindo Pharma Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aurobindo Pharma Limited. The current atr is 31.15.

Aurobindo Pharma Limited Daily Average True Range (ATR) ChartAurobindo Pharma Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aurobindo Pharma Limited. The current obv is 65,194,999.

Aurobindo Pharma Limited Daily On-Balance Volume (OBV) ChartAurobindo Pharma Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aurobindo Pharma Limited. The current mfi is 49.84.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Aurobindo Pharma Limited Daily Money Flow Index (MFI) ChartAurobindo Pharma Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aurobindo Pharma Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Aurobindo Pharma Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aurobindo Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.854
Ma 20Greater thanMa 501,104.885
Ma 50Greater thanMa 1001,063.669
Ma 100Greater thanMa 2001,070.149
OpenGreater thanClose1,109.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Aurobindo with someone you think should read this too:
  • Are you bullish or bearish on Aurobindo? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aurobindo? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aurobindo Pharma Limited

I send you an email if I find something interesting about Aurobindo Pharma Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Aurobindo Pharma Limited.

Receive notifications about Aurobindo Pharma Limited in your mailbox!